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1. EMSC corrected dataset of  Busulfan and Methotrexate




































Figure S1: EMSC corrected and smoothed dataset of A Busulfan from 0mg/mL to 0.05mg/mL 
in the fingerprint region. B: Methotrexate from 0µM to 500µM from 1200cm-1 to 1800cm-1. 
The spectra are offset for clarity.
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2. EMSC corrected data of  Busulfan and Methotrexate at the LOD
Figure S2: EMSC corrected and smoothed dataset of A Busulfan at 0.0002mg/mL in the 
fingerprint region. B: Methotrexate at 10µM from 1200cm-1 to 1800cm-1. The spectra are offset 
for clarity.
3. Root Mean Square Error Cross Validation (RMSECV) plots for Busulfan and 
Methotrexate 









































Figure S3. Evolution of RMSECV for (A) Busulfan and (B) Methotrexate. The RMSECV 
values are calculated to be 0.0003mg/mL for Bu and 4.02µM for MTX
